See Policy CPT/HCPCS CODE section below for any prior authorization requirements

SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

APPLIES TO:

All lines of business

BENEFIT APPLICATION

Medicaid Members

Oregon: Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

POLICY CRITERIA

The use of serological antibody testing for *Helicobacter pylori* is considered **not medically necessary and not covered** for all indications.

Link to Policy Summary

CPT/HCPCS CODES

<table>
<thead>
<tr>
<th>All Lines of Business</th>
<th>Not Covered</th>
</tr>
</thead>
<tbody>
<tr>
<td>86677</td>
<td>Antibody; <em>Helicobacter pylori</em></td>
</tr>
</tbody>
</table>
DESCRIPTION

_Helicobacter pylori_ (H. pylori)

_H. pylori_ is a chronic bacterial infection associated with conditions such as peptic ulcer disease, chronic gastritis, gastric adenocarcinoma, and gastric mucosa associated lymphoid tissue lymphoma. _H. pylori_ generally has no symptoms in up to 90% of people infected. It is estimated that 50% of the world’s population is infected with the bacteria, more commonly found in developing nations. Route of infection is unknown, although it seems that person-to-person transmission through fecal/oral or oral/oral exposure is most likely. _H. pylori_ is treated with antibiotic regimens.¹

**Diagnostic testing**

_H. Pylori_ can be diagnosed through endoscopy using biopsy urease tests, histology, or bacterial culture. Non-invasive options are also available, including urea breath tests, stool antigen tests, and serology. Urea breath tests and stool antigen tests test for active infections, while serology can be positive in patients with active or prior infection.

**Serologic tests**

Serologic tests use ELISA tests to detect IgG antibodies for _H pylori_. They are noninvasive and inexpensive, but require validation at the local level, limiting their value in routine practice.

**REVIEW OF EVIDENCE**

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of serologic testing to diagnose _Helicobacter pylori_. Below is a summary of the available evidence identified through February of 2021.

**Systematic reviews**

In 2018, Cochrane published a systematic review of non-invasive diagnostic tests for _H pylori_ infection, including urea breath test, serology, and stool antigen testing.² The review identified 101 studies that met inclusion criteria, involving 11,003 participants. Of the included diagnostic accuracy studies, 34 evaluated serology, totalling 4242 participants. For serological testing, the diagnostic odds ratio was 47.4 (95% confidence interval [CI], 25.5 to 88.1), and the sensitivity (95% CI) estimated at a fixed specificity of 0.90 was 0.84 (95% CI, 0.74 to 0.91). Direct comparison of urea breath test versus serological testing showed a diagnostic odds ratio of 0.68 (95% CI, 0.12 to 3.70; p=0.56). There was limited data for direct comparison of stool antigen test versus serological test. The authors concluded that urea breath tests had higher diagnostic accuracy compared to serology, but further comparative studies of high methodological quality are needed to determine accuracy.

**Prospective studies**

In 2013, Pourakbari and colleagues published the results of a prospective study comparing rapid urease tests (RUT), serology, histopathology, and stool antigen tests with PCR for the detection of _H pylori_.³
study included 89 participants. Fifty-three participant biopsies were found to be \textit{H pylori} positive through ureC PCR. Correlation of RUT, serology, histopathology, and stool antigen tests with PCR was 0.82, 0.32, 0.91, and 0.63. Serology (IgG) had a sensitivity, specificity, and test accuracy of 50\%, 83.3\%, and 65\%. The authors concluded that RUT and histopathology and as accurate as the PCR of biopsy and stool antigen tests are considered an appropriate noninvasive diagnostic test for \textit{H pylori}, whereas serology was not recommended.

**CLINICAL PRACTICE GUIDELINES**

**American College of Gastroenterology (ACG)**

In 2007, the ACG published practice guidelines for the management of \textit{H pylori} infection. The guidelines state the following: Antibody testing is inexpensive and widely available but poor PPV [positive predictive value] in populations with a low prevalence of \textit{H. pylori} infection limits its usefulness in clinical practice.\(^4\) They recommend urea breath tests and fecal antigen tests as noninvasive diagnostic tools.

In 2017, the ACG updated their guidelines, continuing to recommend urea breath tests for diagnosing \textit{H pylori} infection and testing post-treatment.\(^5\)

**UpToDate**

In 2020, UpToDate published guidelines on diagnostic tests for \textit{H pylori} infection. They state, “Serologic tests require validation at the local level, which is impractical in routine practice. In addition, concerns over its accuracy have limited its use. Guidelines recommend that serologic testing should not be used in low prevalence populations as the low accuracy of serology would result in inappropriate treatment in significant numbers of patients.”\(^6\)

**CENTERS FOR MEDICARE & MEDICAID SERVICES**

As of February 2021, the following retired Centers for Medicare & Medicaid (CMS) coverage guidance was identified addressing \textit{Helicobacter pylori} infection testing:

- RETIRED Local Coverage Determination (LCD): \textit{Helicobacter Pylori} Infection Testing (L37626)\(^7\)
- RETIRED Local Coverage Article: Billing and Coding: \textit{Helicobacter Pylori} Infection Testing (A57227)\(^8\)

Medicare states, “Retirement does not mean that medical necessity has changed or that the LCD no longer reflects appropriate criteria. The guidance in the retired LCD may be helpful in assessing medical necessity.”\(^7\) The policy criteria are in line with the Medicare LCD and LCA guidance.

**POLICY SUMMARY**

Due to the fact that serological testing for \textit{H pylori} infection will produce positive results from both active infection and past exposure, antibody testing has poor positive predictive value. Clinical guidelines therefore recommend against serological testing for \textit{H pylori} in low prevalence populations, such as the United States, in order to prevent inappropriate treatment.
INSTRUCTIONS FOR USE

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days’ notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

REGULATORY STATUS

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

REFERENCES
